# Transarterial Chemoembolization With Lipiodol in the Treatment of Initial Unresectable Gastric Cancer (GC)

> **NCT05361161** · PHASE2 · UNKNOWN · sponsor: **Gang Wu** · enrollment: 60 (estimated)

## Conditions studied

- Gastric Cancer
- Embolization

## Interventions

- **DRUG:** Transarterial Chemoembolization

## Key facts

- **NCT ID:** NCT05361161
- **Lead sponsor:** Gang Wu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-01
- **Primary completion:** 2022-12-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05361161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05361161, "Transarterial Chemoembolization With Lipiodol in the Treatment of Initial Unresectable Gastric Cancer (GC)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05361161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*